2015
DOI: 10.3109/21691401.2015.1047557
|View full text |Cite
|
Sign up to set email alerts
|

Red blood cell replacement, or nanobiotherapeutics with enhanced red blood cell functions?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
13
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(14 citation statements)
references
References 38 publications
1
13
0
Order By: Relevance
“…SFHb contains haemoglobin and red blood cell enzymes including CAT, SOD and CA. The enzyme extracted had been established previously [24,25]. 300 ml bovine SFHb (Hb concentration: 9g/dL) is placed in a beaker on ice.…”
Section: Bovine Enzyme Extraction and MIX With Bovine Stroma-free Haementioning
confidence: 99%
See 1 more Smart Citation
“…SFHb contains haemoglobin and red blood cell enzymes including CAT, SOD and CA. The enzyme extracted had been established previously [24,25]. 300 ml bovine SFHb (Hb concentration: 9g/dL) is placed in a beaker on ice.…”
Section: Bovine Enzyme Extraction and MIX With Bovine Stroma-free Haementioning
confidence: 99%
“…To enhance the red blood cell enzymes, commercial CAT, SOD and CA are added for the preparation of poly-[Hb-CAT-SOD-CA] [20][21][22][23]. For avoiding the high cost of commercial enzymes, a cost-effective novel enzyme extraction method has been established to obtain these three enzymes from SFHb simultaneously [24,25]. This avoids the need for expensive commercial enzymes and allows the large-scale production of poly-[Hb-CAT-SOD-CA] in the future.…”
Section: Introductionmentioning
confidence: 99%
“…The first generation blood substitute is based on the basic principle of polyhemoglobin (PolyHb) (Chang 1964(Chang , 1971). This has been developed independently by others and has undergone extensive clinical trials (Alayash et al 2007, Bian et al 2013, Chang 2014, Chang 2015, Jahr et al 2008, Kim and Greenburg 2014and Zhao et al 2014. It is already approved for routine clinical use in countries where HIV in donor blood is still a major problem.…”
Section: Introductionmentioning
confidence: 99%
“…These life‐saving biologics are expected to revolutionize blood banking and transfusion medicine practices. Patients will benefit from having access to readily available pathogen‐free oxygen‐carrying volume expanders with universal compatibility and prolonged storage and at reasonably low price, with assurance that benefits outweigh any potential risks .…”
mentioning
confidence: 99%
“…A new orthogonal Hb purification technology provides complete removal of viruses and prion proteins . Chemical stabilization of Hb molecule along with modulating its oxygen affinity, creating stable polymeric structures with advanced cross‐linkers, decreasing its pro‐oxidative activity by engineering tyrosine electron transfer pathway and protecting heme by conjugation with antioxidants (i.e., GSH, nitroxyl radicals, SOD, catalase, carbonic anhydrase), alleviating its vasoconstrictive potential by protection of beta 93 cysteine (i.e., with 4,4′‐dithiodipyridine), targeted decoration with PEG, pharmacological modification with vasodilators (i.e., ATP, adenosine, NO‐donors), and CO‐saturated products are taking the lead . Classical Hb encapsulation is still in use and has become more advanced.…”
mentioning
confidence: 99%